摘要
目的:探究依洛尤单抗治疗高脂血症的有效性及安全性。方法:选取2019年12月-2020年12月使用瑞舒伐他汀血脂控制欠佳后联合应用依洛尤单抗治疗的冠心病患者36例,作为试验组;选择同期使用瑞舒伐他汀血脂控制欠佳的冠心病患者36例,作为对照组。比较两组治疗效果。结果:试验组治疗后总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平均明显低于对照组,差异有统计学意义(P<0.05)。两组患者均未见过敏及其他不适症状。结论:依洛尤单抗治疗高脂血症的临床有效性显著,安全性可靠。
Objective:To explore the effectiveness and safety of evolocumab in the treatment of hyperlipidemia.Methods:From December 2019 to December 2020,36 patients with coronary heart disease who were treated with evolocumab after poor lipid control with rosuvastatin were selected as the experimental group.Another 36 patients with coronary heart disease whose blood lipids were poorly controlled by rosuvastatin in the same period were selected as the control group.The treatment effects of the two groups were compared.Results:After treatment,the total cholesterol,triglyceride and low density lipoprotein C levels in the experimental group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).There were no allergy or other discomfort symptoms of patients in the two groups.Conclusion:Evolocumab has significant clinical effectiveness and reliable safety in the treatment of hyperlipidemia.
作者
易小莹
高振
魏云杰
张涛
党书毅
Yi Xiao-ying;Gao Zhen;Wei Yun-jie;Zhang Tao;Dang Shu-yi(Department of Cardiology,Postgraduate Training Base of Jinzhou Medical University,Shiyan Taihe Hospital,Jinzhou 121000,Liaoning Province,China;Department of Cardiology,Taihe Hospital Affiliated to Hubei University of Medicine,Shiyan 442000,Hubei Province,China)
出处
《中国社区医师》
2022年第1期66-68,共3页
Chinese Community Doctors
基金
湖北省科技厅研项目(项目编号:2018CFB747,2018CFB537)
湖北省教育厅科研项目(项目编号:B2017112,B20181130)
十堰市科技局项目(项目编号:18Y42)。
